Based on this scoring, the cancer cohort was then divided into two groups, a positive (or high expression) group that showed positive nuclear DDX21 staining in ≥ 10% of cancer cells, and a negative (or low expression) group that showed negative staining or staining in < 10% of cancer cells. Here, DDX21 is linked to cancer.